Serum C-reactive protein level in COPD patients stratified according to GOLD 2011 grading classification
- PMID: 28083044
- PMCID: PMC5216300
- DOI: 10.12669/pjms.326.10905
Serum C-reactive protein level in COPD patients stratified according to GOLD 2011 grading classification
Abstract
Background and objective: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 grading classification has been used to evaluate the severity of patients with chronic obstructive pulmonary disease (COPD). However, little is known about the relationship between the systemic inflammation and this classification. We aimed to study the relationship between serum CRP and the components of the GOLD 2011 grading classification.
Methods: C-reactive protein (CRP) levels were measured in 391 clinically stable COPD patients and in 50 controls from June 2, 2015 to October 31, 2015 in the First Affiliated Hospital of Xiamen University. The association between CRP levels and the components of the GOLD 2011 grading classification were assessed.
Results: Correlation was found with the following variables: GOLD 2011 group (0.240), age (0.227), pack year (0.136), forced expiratory volume in one second % predicted (FEV1%; -0.267), forced vital capacity % predicted (-0.210), number of acute exacerbations in the past year (0.265), number of hospitalized exacerbations in the past year (0.165), British medical Research Council dyspnoea scale (0.121), COPD assessment test score (CAT, 0.233). Using multivariate analysis, FEV1% and CAT score manifested the strongest negative association with CRP levels.
Conclusions: CRP levels differ in COPD patients among groups A-D based on GOLD 2011 grading classification. CRP levels are associated with several important clinical variables, of which FEV1% and CAT score manifested the strongest negative correlation.
Keywords: C-reactive protein; Chronic obstructive pulmonary disease; GOLD 2011 Grading Classification; Systemic inflammation.
Conflict of interest statement
Declaration of interest: All authors declared there was no conflict interests involved.
References
-
- Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370:741–750. doi:10.1016/S0140-6736(07)61377-4. - PubMed
-
- Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet. 1997;349:1498–1504. doi:10.1016/S0140-6736(96)07492-2. - PubMed
-
- GOLD Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2011. http://www.goldcopd.com .
-
- De Torres J, Cordoba-Lanus E, Lopez-Aguilar C, de Fuentes MM, de Garcini AM, Aguirre-Jaime A, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006;27:902–907. doi:10.1183/09031936.06.00109605. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous